249 related articles for article (PubMed ID: 36658220)
21. Expression of EWS-ETS fusions in NIH3T3 cells reveals significant differences to Ewing's sarcoma.
Braunreiter CL; Hancock JD; Coffin CM; Boucher KM; Lessnick SL
Cell Cycle; 2006 Dec; 5(23):2753-9. PubMed ID: 17172842
[TBL] [Abstract][Full Text] [Related]
22. A novel role for keratin 17 in coordinating oncogenic transformation and cellular adhesion in Ewing sarcoma.
Sankar S; Tanner JM; Bell R; Chaturvedi A; Randall RL; Beckerle MC; Lessnick SL
Mol Cell Biol; 2013 Nov; 33(22):4448-60. PubMed ID: 24043308
[TBL] [Abstract][Full Text] [Related]
23. EWS-FLI1 regulates and cooperates with core regulatory circuitry in Ewing sarcoma.
Shi X; Zheng Y; Jiang L; Zhou B; Yang W; Li L; Ding L; Huang M; Gery S; Lin DC; Koeffler HP
Nucleic Acids Res; 2020 Nov; 48(20):11434-11451. PubMed ID: 33080033
[TBL] [Abstract][Full Text] [Related]
24. A Druggable Rheostat for Ewing Sarcoma?
Weiss KR; Bailey KM
Clin Cancer Res; 2022 Oct; 28(20):4360-4362. PubMed ID: 35921177
[TBL] [Abstract][Full Text] [Related]
25. Identification of two types of GGAA-microsatellites and their roles in EWS/FLI binding and gene regulation in Ewing sarcoma.
Johnson KM; Taslim C; Saund RS; Lessnick SL
PLoS One; 2017; 12(11):e0186275. PubMed ID: 29091716
[TBL] [Abstract][Full Text] [Related]
26. Clinical and biochemical function of polymorphic NR0B1 GGAA-microsatellites in Ewing sarcoma: a report from the Children's Oncology Group.
Monument MJ; Johnson KM; McIlvaine E; Abegglen L; Watkins WS; Jorde LB; Womer RB; Beeler N; Monovich L; Lawlor ER; Bridge JA; Schiffman JD; Krailo MD; Randall RL; Lessnick SL
PLoS One; 2014; 9(8):e104378. PubMed ID: 25093581
[TBL] [Abstract][Full Text] [Related]
27. Promiscuous partnerships in Ewing's sarcoma.
Sankar S; Lessnick SL
Cancer Genet; 2011 Jul; 204(7):351-65. PubMed ID: 21872822
[TBL] [Abstract][Full Text] [Related]
28. MiR-30a-5p connects EWS-FLI1 and CD99, two major therapeutic targets in Ewing tumor.
Franzetti GA; Laud-Duval K; Bellanger D; Stern MH; Sastre-Garau X; Delattre O
Oncogene; 2013 Aug; 32(33):3915-21. PubMed ID: 22986530
[TBL] [Abstract][Full Text] [Related]
29. EWS/ETS-Driven Ewing Sarcoma Requires BET Bromodomain Proteins.
Gollavilli PN; Pawar A; Wilder-Romans K; Natesan R; Engelke CG; Dommeti VL; Krishnamurthy PM; Nallasivam A; Apel IJ; Xu T; Qin ZS; Feng FY; Asangani IA
Cancer Res; 2018 Aug; 78(16):4760-4773. PubMed ID: 29898995
[TBL] [Abstract][Full Text] [Related]
30. Synthetic siRNA targeting the breakpoint of EWS/Fli-1 inhibits growth of Ewing sarcoma xenografts in a mouse model.
Takigami I; Ohno T; Kitade Y; Hara A; Nagano A; Kawai G; Saitou M; Matsuhashi A; Yamada K; Shimizu K
Int J Cancer; 2011 Jan; 128(1):216-26. PubMed ID: 20648560
[TBL] [Abstract][Full Text] [Related]
31. Oncogenic ETS fusions deregulate E2F3 target genes in Ewing sarcoma and prostate cancer.
Bilke S; Schwentner R; Yang F; Kauer M; Jug G; Walker RL; Davis S; Zhu YJ; Pineda M; Meltzer PS; Kovar H
Genome Res; 2013 Nov; 23(11):1797-809. PubMed ID: 23940108
[TBL] [Abstract][Full Text] [Related]
32. Ewing sarcoma cells secrete EWS/Fli-1 fusion mRNA via microvesicles.
Tsugita M; Yamada N; Noguchi S; Yamada K; Moritake H; Shimizu K; Akao Y; Ohno T
PLoS One; 2013; 8(10):e77416. PubMed ID: 24124617
[TBL] [Abstract][Full Text] [Related]
33. A novel oncogenic mechanism in Ewing sarcoma involving IGF pathway targeting by EWS/Fli1-regulated microRNAs.
McKinsey EL; Parrish JK; Irwin AE; Niemeyer BF; Kern HB; Birks DK; Jedlicka P
Oncogene; 2011 Dec; 30(49):4910-20. PubMed ID: 21643012
[TBL] [Abstract][Full Text] [Related]
34. Hippo pathway effectors YAP1/TAZ induce an EWS-FLI1-opposing gene signature and associate with disease progression in Ewing sarcoma.
Rodríguez-Núñez P; Romero-Pérez L; Amaral AT; Puerto-Camacho P; Jordán C; Marcilla D; Grünewald TG; Alonso J; de Alava E; Díaz-Martín J
J Pathol; 2020 Apr; 250(4):374-386. PubMed ID: 31880317
[TBL] [Abstract][Full Text] [Related]
35. Chromatin profiling reveals relocalization of lysine-specific demethylase 1 by an oncogenic fusion protein.
Theisen ER; Selich-Anderson J; Miller KR; Tanner JM; Taslim C; Pishas KI; Sharma S; Lessnick SL
Epigenetics; 2021 Apr; 16(4):405-424. PubMed ID: 32842875
[TBL] [Abstract][Full Text] [Related]
36. Therapeutic opportunities in Ewing sarcoma: EWS-FLI inhibition via LSD1 targeting.
Theisen ER; Pishas KI; Saund RS; Lessnick SL
Oncotarget; 2016 Apr; 7(14):17616-30. PubMed ID: 26848860
[TBL] [Abstract][Full Text] [Related]
37. Expression of the EWS/FLI-1 oncogene in murine primary bone-derived cells Results in EWS/FLI-1-dependent, ewing sarcoma-like tumors.
Castillero-Trejo Y; Eliazer S; Xiang L; Richardson JA; Ilaria RL
Cancer Res; 2005 Oct; 65(19):8698-705. PubMed ID: 16204038
[TBL] [Abstract][Full Text] [Related]
38. EWS::FLI1 and HOXD13 Control Tumor Cell Plasticity in Ewing Sarcoma.
Apfelbaum AA; Wu F; Hawkins AG; Magnuson B; Jiménez JA; Taylor SD; Wrenn ED; Waltner O; Pfaltzgraff ER; Song JY; Hall C; Wellik DM; Ljungman M; Furlan SN; Ryan RJH; Sarthy JF; Lawlor ER
Clin Cancer Res; 2022 Oct; 28(20):4466-4478. PubMed ID: 35653119
[TBL] [Abstract][Full Text] [Related]
39. Microsatellites are EWS/FLI response elements: genomic "junk" is EWS/FLI's treasure.
Gangwal K; Lessnick SL
Cell Cycle; 2008 Oct; 7(20):3127-32. PubMed ID: 18927503
[TBL] [Abstract][Full Text] [Related]
40. Blocking the road, stopping the engine or killing the driver? Advances in targeting EWS/FLI-1 fusion in Ewing sarcoma as novel therapy.
Kovar H
Expert Opin Ther Targets; 2014 Nov; 18(11):1315-28. PubMed ID: 25162919
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
